Jazz Pharmaceuticals (JAZZ) PT Lowered to $129 at Piper Sandler
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/27/2026
- Wall Street ends higher on revived AI momentum
- Meta's $97.5B AI money grab: why Zuckerberg is racing to raise cash before rivals
- Deutsche Bank’s Reid sees potential final dip this year before Santa rally
- UPS tops estimates as efficiency drive gains momentum
- GM to move stock listing to Nasdaq in November, shares gain
Tweet
Share
E-mailGet Alerts JAZZ Hot Sheet
Price: $206.78 +0.53%
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Rating Summary:
33 Buy, 5 Hold, 0 Sell
Rating Trend: = Flat
Today's Overall Ratings:
Up: 11 | Down: 18 | New: 18
Join SI Premium – FREE
Piper Sandler analyst David Amsellem lowered the price target on Jazz Pharmaceuticals (NASDAQ: JAZZ) to $129.00 (from $142.00) while maintaining a Neutral rating.
You May Also Be Interested In
- Applied Industrial Technologies (AIT) PT Lowered to $360 at KeyBanc
- Ramelius Resources (RMS:AU) (RMLRF) PT Raised to AUD6.65 at Canaccord
- Stella-Jones Inc. (SJ:CN) (STLJF) PT Lowered to Cdn$76 at CIBC
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
